Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

News-Medical
news-medical.net-medical.net

FDA clears trial of dual-targeted CAR T-cell therapy for cancer

2+ day, 16+ hour ago   (778+ words) The U.S. Food and Drug Administration this week granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who…...

Business Upturn
businessupturn.com > brand-post > car-t-cell-therapy-for-nhl-clinical-trial-landscape-expands-over-70-companies-advancing-next-generation-therapies-delveinsight

CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight

3+ day, 20+ hour ago   (184+ words) New York, USA, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CAR T-cell Therapy for NHL Clinical Trial Landscape Expands: Over 70 Companies Advancing Next-Generation Therapies | DelveInsight The CAR T-cell therapy for NHL clinical trial analysis report delivers important insights into ongoing research of 75+ pipeline CAR…...

news.cuanschutz.edu
news.cuanschutz.edu > news-stories > your-blog-fda-clears-clinical-trial-using-car-t-cells-to-fight-colorectal-cancer

FDA Clears Clinical Trial Using CAR T-Cells to Fight Colorectal Cancer

3+ day, 22+ hour ago   (801+ words) The FDA has cleared a CU Anschutz clinical trial of an experimental CAR T-cell therapy for advanced colorectal cancer and pediatric solid tumors. Developed at CU Anschutz, the therapy targets two pathways that help tumors grow and evade the immune…...

BIOENGINEER.ORG
bioengineer.org > rare-muscle-infiltrating-t-cell-lymphoma-in-a-dog-challenges-diagnosis

Rare Muscle-Infiltrating T-Cell Lymphoma in a Dog Challenges Diagnosis

3+ day, 17+ hour ago   (85+ words) A ten-year-old castrated male mixed breed dog walked into his routine wellness visit with what looked like a minor soft tissue problem: mild swelling around the right hock. Within days, that swelling had exploded into severe pitting edema along an…...

Mirage News
miragenews.com > fda-approves-car-t-cell-trials-for-colorectal-1742264

FDA Approves CAR T-Cell Trials for Colorectal Cancer

3+ day, 23+ hour ago   (737+ words) The U.S. Food and Drug Administration has granted permission for investigators at the University of Colorado Anschutz to conduct a clinical trial testing genetically engineered immune cells in adults with advanced colorectal cancer and pediatric patients with solid cancers who have…...

BIOENGINEER.ORG
bioengineer.org > measuring-how-target-antigen-levels-drive-car-t-cell-efficacy-in-aml

Measuring how target antigen levels drive CAR T-cell efficacy in AML

4+ day, 14+ hour ago   (857+ words) Bioengineer.org...

Cleveland Clinic
consultqd.clevelandclinic.org > patient-case-study-car-t-cell-therapy-leads-to-complete-remission-for-relapsed-al-amyloidosis

Patient with AL Amyloidosis Experiences Complete Remission after CAR T-Cell Therapy

5+ day, 11+ hour ago   (607+ words) Treatment yields positive results despite late diagnosis and cardiac involvement AL amyloidosis is a complex disease that’s vexing to diagnose. The diagnostic journey can exceed 15 years in some cases. In this instance, a woman in her 50s had struggled with low…...

Macau Business
macaubusiness.com > pepromene-bio-announces-publication-in-the-lancet-of-breakthrough-phase-1-clinical-trial-results-demonstrating-deep-and-durable-complete-responses-in-relapsed-refractory-b-cell-lymphomas-including-13

PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure

5+ day, 10+ hour ago   (152+ words) IRVINE, Calif., Sept. 8, 2026 /PRNewswire/ — PeproMene Bio, Inc. today announced the publication in The Lancet, one of the world’s leading medical journals, of results from its Phase 1 clinical trial evaluating PMB-CT01, the company’s first-in-class BAFF-R-targeted CAR T-cell therapy, in patients with…...

WashU Medicine
medicine.washu.edu > impact > cancer > car-t-therapy

CAR-T Therapy

6+ day, 2+ hour ago   (252+ words) Whether you are part of our community or are interested in joining us, we welcome you to WashU Medicine. A game-changing innovation in blood cancer treatment An innovative cell-based immunotherapy developed by WashU Medicine researchers is changing the paradigm of…...

Google News
asiatimes.com > 2026 > 09 > cheaper-car-t-therapy-drawing-global-cancer-patients-to-china

Cheaper CAR-T therapy drawing global cancer patients to China

6+ day, 6+ hour ago   (869+ words) At 25, Michael Walters had already endured unsuccessful lymphoma treatments in New Zealand. A Melbourne hospital quoted up to US$600,000 for CAR-T therapy. He paid less than half that in Shanghai and learned on August 18 that his cancer was in complete…...